Ph.D., Co-founder and CEO, Guardant Health
Helmy Eltoukhy, PhD, is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. Helmy’s prior startup, Avantome, was a leader in low-cost sequencing before being acquired by Illumina. Helmy served as the senior director of scientific research at Illumina, where he was responsible for the development of novel chemistries, hardware, and informatics for genetics analysis systems.Helmy began his career at the Stanford Genome Technology Center, where he invented the first semiconductor sequencing platform and the first base-calling algorithm for next-gen sequencing. He earned his PhD, MS, and BS degrees in electrical engineering from Stanford.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: The development of small robust mutation panels for cancer screening represents a next step in changing the focus of cancer research from late-stage to early disease identification. This session will focus on the progress of early cancer detection and its critical step in reducing cancer deaths in the long term.